Aaron S Kesselheim MD

Hospital Medicine/Hospitalist

Assistant Professor of Medicine, Brigham and Women's Hospital

Education & Training

Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Perelman School of Medicine at the University of PennsylvaniaClass of 2002

PubMed

Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US.
Benjamin N Rome, Jihye Han, Helen Mooney, Aaron S Kesselheim
JAMA Dermatology. 2025-04-16
Design Patents: A Potential Threat to Drug Competition.
Janet Freilich, Aaron S Kesselheim
Applied Health Economics and Health Policy. 2025-04-08
Changes in Oncology Medication Use After Withdrawal of Accelerated Approval.
Catherine S Hwang, Aaron S Kesselheim, Amar H Kelkar, Edward R Scheffer Cliff, Benjamin N Rome
JAMA Oncology. 2025-04-03

Journal Articles

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Aaron Kesselheim, MD, JAMA Internal Medicine
Substitution of Generic Drugs and Biosimilars—Reply
Aaron Kesselheim, MD, JAMA Internal Medicine
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions
Aaron Kesselheim, MD, JAMA Internal Medicine
Drug Prices, Rebates, and Discounts
William B Feldman, Aaron S Kesselheim, JAMA
Missed Opportunities on Emergency Remdesivir Use
Aaron Kesselheim, MD, JAMA
False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications
Steven Woloshin, Aaron S Kesselheim, The New England Journal of Medicine
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies
Mike Z Zhai, Carolyn T Lye, Aaron S Kesselheim, JAMA Internal Medicine
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act
Florence T Bourgeois, Aaron S Kesselheim, JAMA
Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012
Aaron S Kesselheim, Michael S Sinha, JAMA
Medicare Spending on Brand-Name Combination Medications vs Their Generic Constituents
Aaron Kesselheim, MD, JAMA
Feature Patent Term Restoration for Top-Selling Drugs in the USA
Aaron Kesselheim, MD, ScienceDirect
Join now to see all

Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
Drug Prices, Rebates, and DiscountsJuly 2020
US Spending Associated with Transition from Daily to 3-Times-Weekly Glatiramer AcetateJuly 2020
US Spending Associated with Transition from Daily to 3-Times-Weekly Glatiramer AcetateJuly 2020
Prices of Generic Drugs Associated with Numbers of ManufacturersDecember 2017
Prices of Generic Drugs Associated with Numbers of ManufacturersDecember 2017
Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United StatesNovember 2017
Join now to see all

Colin Edgerton, MD, Testifies in Biosimilars HearingApril 21st, 2025
Medicare Spends Billions on Oncology Drugs Offering Little Added BenefitApril 4th, 2025
Trump’s FDA Pick Made His Name by Bashing the Medical Establishment. Soon He May Be Leading ItMarch 4th, 2025
Join now to see all

Off-Label Prescribing: Comparative Evidence, Regulation, And UtilizationAgency For Healthcare Research And Quality2009–2011